Bone Graft News and Research

RSS

BioMimetic granted Canadian notice of patent allowance covering rhPDGF-BB platform technology formulations

BioMimetic Therapeutics, Inc. announced today the Canadian Intellectual Property Office (CIPO) has allowed patent application No. 2,583,823 titled "Platelet Derived Growth Factor (PDGF) Compositions and Methods of Use Thereof". The new patent will remain in force until October 2025, during which time it will prohibit the marketing of similar or generic versions of the Company's Augment™ orthopedic product line and certain other rhPDGF-BB product formulations.

17 Dec 2010

Orthovita granted FDA marketing clearance for Vitoss Bioactive Foam-2X Bone Graft Substitute

Orthovita, Inc. , an orthobiologics and biosurgery company, announced today that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market Vitoss Bioactive Foam-2X Bone Graft Substitute for use as a non-structural bone void filler for use in the spine, pelvis and extremities. Orthovita expects to launch the newest addition to its bone graft substitute product line by late February or early March of 2011.

7 Dec 2010

Bacterin secures $8 million financing from WTI

Bacterin International Holdings, Inc., a creator and developer of revolutionary bone graft material and anti-infective coatings for medical applications, today announced that it has secured an asset based lending facility of up to $8.0 million from Western Technology Investment, and has received approximately $980,000 through the exercise of warrants for a total of approximately $9 million potentially available for the Company's use.

22 Nov 2010

Bacterin third quarter revenue increases from $1.4 million to $4.2 million

Bacterin International Holdings, Inc., a developer of anti-infective coatings for medical applications and revolutionary bone graft material, today reported financial results for its third quarter ended September 30, 2010.

15 Nov 2010

Spinal Column: New blog on spinal disorders

Clinicians seeking insight into the latest research on spinal disorders and its impact on their everyday clinical practice will find it in "The Spinal Column," a new weekly blog found on the Spine website. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health, a leading provider of information and business intelligence for students, professionals, and institutions in medicine, nursing, allied health, and pharmacy.

11 Nov 2010

Wright Medical launches PRO-STIM Injectable Inductive Graft

Wright Medical Group, Inc. a global orthopaedic medical device company, is pleased to announce the full commercial launch of PRO-STIM Injectable Inductive Graft.

22 Oct 2010

Orthovita 2010 third quarter increases 5% to $23.3 million

Orthovita, Inc., an orthobiologics and biosurgery company, today announced that product sales for the third quarter of 2010 were $23.3 million, a 5% increase over product sales of $22.3 million in the third quarter of 2009.

21 Oct 2010

Pioneer Surgical receives patent for nanOss technology

Pioneer Surgical Technology, Inc., a global medical device provider in orthopaedics, spine, and biologics, is proud to announce the United States Patent Office has reissued a patent further strengthening Pioneer's market position in nanocrystalline derived products used in orthopaedics.

6 Oct 2010

Titan Spine to release new Endoskeleton TC system in first-quarter 2011

Titan Spine announced that it will begin full commercial release of its new Endoskeleton® TC system first quarter of 2011. The Endoskeleton® TC is an interbody fusion device for the cervical spine. The product received 510(k) clearance in July of this year and has been in limited market release since early August. The device has an acid etched titanium surface and is biomechanically designed to promote spinal fusion.

4 Oct 2010

FDA clears Orthovita's VITOMATRIX Bone Graft Substitute for dental procedures

Orthovita, Inc., an orthobiologics and biosurgery company, announced that it received 510(k) clearance from the U.S. Food and Drug Administration to market VITOMATRIX Bone Graft Substitute as a bone grafting material in certain dental procedures.

4 Oct 2010

FDA approves NovaBone Putty MIS Delivery System for orthopedic surgery

NovaBone Products, a medical device company, today announces the U.S. Food and Drug Administration's (FDA) approval of the NovaBone Putty® MIS Delivery System designed for use in minimally invasive orthopedic procedures.

4 Oct 2010

Athersys signs agreement with RTI Biologics for MAPC technology access

RTI Biologics Inc., a leading provider of orthopedic and other biologic implants, and Athersys Inc. a leader in regenerative medicine and cell therapy research and development, announced today an agreement under which Athersys will provide RTI access to its Multipotent Adult Progenitor Cell (MAPC) technologies.

13 Sep 2010

NovaSterilis issued US patent

NovaSterilis Inc. has been issued US Patent # 7,771,652 B2 for “Combined Use of an Alkaline Earth Metal Compound and a Sterilizing Agent to Maintain Osteoinduction Properties of a Demineralized Bone Matrix”

9 Sep 2010

BioMimetic completes 100 day PMA meeting with FDA for Augment Bone Graft

BioMimetic Therapeutics, Inc. today announced it completed its 100 day Premarket Approval Application (PMA) meeting with the Food and Drug Administration (FDA) regarding the review of Augment™ Bone Graft for the treatment of foot and ankle fusions in the U.S. The FDA generally meets with the PMA sponsor approximately 100 days after the filing of the PMA with the purpose of discussing the status of the application.

9 Sep 2010

Interventional Spine completes another successful surgery with PERPOS Percutaneous Cervical System

Interventional Spine, Inc. today announced the completion of another successful surgery with the unique PERPOS Percutaneous Cervical System for the treatment of neck pain.

16 Aug 2010

Osteotech second-quarter revenue increases 2% to $24.0 million

Osteotech, Inc., a leader in the emerging field of biologic products for regenerative healing, today reported financial results for the second quarter ended June 30, 2010.

9 Aug 2010

Bacterin International closes private placement

Bacterin International Holdings, Inc., a developer of anti-infective coatings for medical applications and revolutionary bone graft material, today announced that it has closed its private placement offering raising total gross proceeds of $9.2 million from the sale to accredited investors, including certain of its directors and officers, of shares of its common stock at a purchase price of $1.60 per share, with detachable warrants to purchase one-quarter of one share its common stock (at an exercise price of $2.50 per share) for each share purchased.

7 Aug 2010

BioMimetic Therapeutics reports net loss of $7.7M for second-quarter 2010

BioMimetic Therapeutics, Inc. today reported its financial results as of and for the three and six months ended June 30, 2010. For the three months ended June 30, 2010, the Company reported a net loss of $7.7 million, or $0.35 per diluted share, compared to a net loss of $6.3 million, or $0.32 per diluted share, for the same period in 2009. For the six months ended June 30, 2010, the Company reported a net loss of $16.2 million, or $0.73 per diluted share, compared to a net loss of $14.3 million, or $0.75 per diluted share, for the same period in 2009.

6 Aug 2010

RTI Biologics second-quarter worldwide revenues in sports medicine increase 14%

RTI Biologics Inc., a leading processor of orthopedic and other biologic implants, reported operating results for the second quarter ended June 30, 2010.

5 Aug 2010

Orthovita second-quarter operating income improves to $0.4 million

Orthovita, Inc., an orthobiologics and biosurgery company, reported financial results for the quarter ended June 30, 2010. Product sales for the second quarter of 2010 were $23.9 million compared to $24.5 million for the second quarter of 2009. Product sales for the second quarter of 2009 included $0.6 million from the sale of Vitomatrix™, a bone graft material used in dental products. There were no Vitomatrix sales in the second quarter of 2010 and no further sales of Vitomatrix are currently expected.

3 Aug 2010